LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Начало・Списък с акции・AbCellera Biologics Inc

AbCellera Biologics Inc

Затворен

СекторЗдравеопазване

5.61 -12.07

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

5.5

Максимум

5.65

Ключови измерители
By Trading Economics
Приходи	-34M -43M
Продажби	-37M 8.3M
EPS	-0.14
Марж на печалбата	-519.122
Служители	562
EBITDA	-31M -49M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+67.26% upside

Дивиденти
By Dow Jones
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	370M 2B
Предишно отваряне	17.68
Предишно затваряне	5.61

Настроения в новините

By Acuity

37%

63%

87 / 344 Класиране в Healthcare

AbCellera Biologics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.06.2026 г., 19:20 ч. UTC

Значими двигатели на пазара

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

6.06.2026 г., 12:40 ч. UTC

Придобивния, сливания и поглъщания

Correction to Texas Billionaires Article America's Resort -- WSJ

6.06.2026 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

6.06.2026 г., 08:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

6.06.2026 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.06.2026 г., 00:14 ч. UTC

Придобивния, сливания и поглъщания

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5.06.2026 г., 21:27 ч. UTC

Печалби

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.06.2026 г., 20:20 ч. UTC

Придобивния, сливания и поглъщания

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5.06.2026 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5.06.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

5.06.2026 г., 19:26 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

5.06.2026 г., 19:26 ч. UTC

Пазарно говорене

Hog Futures Tumble to Close Week -- Market Talk

5.06.2026 г., 19:10 ч. UTC

Пазарно говорене

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5.06.2026 г., 19:03 ч. UTC

Пазарно говорене

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5.06.2026 г., 18:59 ч. UTC

Пазарно говорене

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5.06.2026 г., 18:47 ч. UTC

Пазарно говорене

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5.06.2026 г., 18:34 ч. UTC

Пазарно говорене

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5.06.2026 г., 18:33 ч. UTC

Придобивния, сливания и поглъщания

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5.06.2026 г., 17:50 ч. UTC

Печалби

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5.06.2026 г., 17:27 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5.06.2026 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

5.06.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

5.06.2026 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5.06.2026 г., 15:26 ч. UTC

Пазарно говорене

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5.06.2026 г., 15:25 ч. UTC

Печалби

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

AbCellera Biologics Inc Прогноза

Ценова цел

By TipRanks

67.26% нагоре

12-месечна прогноза

Среден 9.4 USD 67.26%

Висок 13 USD

Нисък 7 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за AbCellera Biologics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на AbCellera Biologics Inc през последните 3 месеца.

Настроение

By Acuity

87 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.